Buscar
Mostrando ítems 1-10 de 130
Laronidase for treating mucopolysaccharidosis type I
(Funpec-editora, 2007-01-01)
Mucopolysaccharidoses are a group of inherited metabolic diseases caused by the absence or deficiency of the lysosomal enzymes that are needed for breaking down glycosaminoglycans (GAGs). Over time, GAGs collect in cells, ...
Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
(2011)
Background/Aims Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disorder treated with bone marrow transplantation or enzyme replacement therapy with laronidase, a high-cost orphan drug. Laronidase was ...
Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy
(Elsevier B.V., 2008-01-01)
Background: Mucopolysaccharidosis type I (NIPS 1) patients present a wide range of clinical manifestations, which could be due to the high molecular heterogeneity of the IDUA gene and to pathological events besides the ...
Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients
(Academic Press Inc Elsevier ScienceSan DiegoEUA, 2003)
Analysis of male reproductive parameters in a murine model of mucopolysaccharidosis type I (MPS I)
(E-century Publishing Corp, 2014-01-01)
Mucopolysaccharidosis (MPS) I is a lysosomal storage disorder (LSD) that is characterised by alpha-L-idu-ronidase (Idua) deficiency and continuous deposition of glycosaminoglycans (GAGs), which consequently interferes with ...